益气化瘀补肺汤对中晚期非小细胞肺癌化疗患者免疫功能及远期生存的影响

目的：观察益气化瘀补肺汤对中晚期非小细胞肺癌（NSCLC） 化疗患者免疫功能及远期生存的影响。方法：选取136例中晚期NSCLC患者，按照随机数字表法分为观察组、对照组各68例。治疗期间，观察组剔除1例，对照组剔除4例，最终纳入研究观察组67例、对照组64例。对照组给予多西他赛联合顺铂方案化疗，观察组在对照组基础上给予益气化瘀补肺汤治疗。比较2组近期疗效，化疗前后肿瘤患者生活质量评分量表（QOL） 评分、免疫功能指标水平，治疗期间不良反应发生率，以及中位生存时间。结果：化疗后，观察组总缓解率59.70%，高于对照组42.19%（P＜0.05）。化疗后，2组社会功能、躯体功能、心理功能评分均较化疗前升高（P＜0.05），观察组社会功能、躯体功能、心理功能评分均高于对照组（P＜0.05）。化疗后，2组CD4+水平均较化疗前降低（P＜0.05），CD8+水平均较化疗前升高（P＜0.05）；观察组CD3+、CD4+水平及CD4+/CD8+值均高于对照组（P＜0.05），CD8+水平低于对照组（P＜0.05）。化疗期间，观察组不良反应总发生率4.48%，低于对照组17.19% （P＜0.05）。观察组中位生存时间25个月，95%CI 15.223～34.777，对照组中位生存时间16个月，95%CI 17.684～24.316，2组比较，差异有统计学意义（Log Rank P＜0.05）。结论：益气化瘀补肺汤可有效提高中晚期NSCLC化疗患者的近期疗效，有助于保护免疫功能，减少化疗期间严重不良反应发生，提高生活质量，延长患者的生存期。

Effect of Yiqi Huayu Bufei Decoction on Immune Function and Long-Term Survival inPatients with Middle-Advanced Stage Non-Small Cell Lung Carcinoma UndergoingChemotherapy

Abstract： Objective： To observe the effect of Yiqi Huayu Bufei Decoction on immune function andlong-term survival in patients with middle-advanced stage non-small cell lung carcinoma (NSCLC)undergoing chemotherapy. Methods：A total of 136 cases of patients with middle-advanced stage NSCLCwere selected and divided into the observation group and the control group according to the random numbertable method， with 68 cases in each group. During treatment， one case was excluded from theobservation group， and four cases were excluded from the control group； finally， 67 cases in theobservation group and 64 cases in the control group were included. The control group was treated withchemotherapy with a combination of docetaxel and cisplatin regimen， and the observation group wasadditionally treated with Yiqi Huayu Bufei Decoction based on the treatment of the control group. Shorttermcurative effects， the scores of the Quality of Life Scale (QOL) of cancer patients and the levels ofimmune function indicators before and after chemotherapy， the incidence of adverse reactions duringtreatment， and median survival time were compared between the two groups. Results： Afterchemotherapy，the total remission rate was 59.70% in the observation group，higher than that of 42.19%in the control group (P＜0.05). After chemotherapy，the scores of social functioning，physical functioning，and psychological functioning in the two groups were increased when compared with those beforechemotherapy (P＜0.05)， and the scores of social functioning， physical functioning， and psychologicalfunctioning in the observation group were higher than those in the control group (P＜0.05). Afterchemotherapy， the levels of CD4+ in the two groups were decreased when compared with those beforechemotherapy (P＜0.05)， and the levels of CD8+ were increased when compared with those beforechemotherapy (P＜0.05)；the levels of CD3+，CD4+，and CD4+/CD8+ in the observation group were higherthan those in the control group (P＜0.05)， and the level of CD8+ in the observation group was lower thanthat in the control group (P＜0.05). During chemotherapy， the total incidence of adverse reactions was4.48% in the observation group， lower than that of 17.19% in the control group (P＜0.05). The mediansurvival time was 25 months in the observation group， with 95%CI 15.223-34.777， and the mediansurvival time was 16 months in the control group， with 95%CI 17.684-24.316， the difference beingsignificant (Log Rank P＜0.05). Conclusion：Yiqi Huayu Bufei Decoction can effectively improve the shorttermcurative effects on patients with middle-advanced stage NSCLC， which can help protect immunefunction，reduce the occurrence of severe adverse reactions during chemotherapy，improve quality of life，and prolong their survival time.